The Dystrophic Epidermolysis bullosa clinical pipeline comprises 20+ notable therapeutic agents in different stages of clinical development varying from Gene therapies, Cell therapies, RNA‐targeting therapy, Protein therapies, Topical therapies, and Small molecules.
DelveInsight’s ‘Dystrophic Epidermolysis Bullosa (DEB) Pipeline Insights’ report presents a complete picture of the available therapies, Dystrophic Epidermolysis Bullosa emerging therapies in different phases of clinical development, key companies working in the Dystrophic Epidermolysis Bullosa pipeline domain, and future potential of the space.
Some of the focal points picked from the Dystrophic Epidermolysis Bullosa Pipeline report:
Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight
The Dystrophic Epidermolysis Bullosa Pipeline reports offer a holistic scenario of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Dystrophic Epidermolysis Bullosa domain.
Dystrophic Epidermolysis Bullosa: Overview
Epidermolysis Bullosa (EB) is a group of inherited disorders that causes blistering, which in several cases can be life-threatening to newborns and infants. It predominantly affects the skin and mucous membrane. A subtype of Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa (DEB) is characterized by the site of blister formation in the lamina densa within the basement membrane zone and the upper dermis.
Dystrophic Epidermolysis Bullosa Pipeline Drugs
Drug
Company
Phase
MoA
RoA
RGN-137
RegeneRx Biopharmaceuticals
Phase II
Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants
Topical
B-VEC
Krystal biotech
Phase III
Gene transference
FCX-007
Castle Creek Biosciences
Cell replacements; Collagen type VII replacements
Intradermal
Research programme- Ribosomal modulators
Zikani Therapeutics
Preclinical
Ribosomal RNA modulators
NA
AGLE-102
Aegle Therapeutics
Phase I/II
Collagen type VII replacements
PTR-01
Phoenix Tissue Repair
Intravenous
TXA127
Constant Therapeutics
Proto-oncogene protein c-mas-1 agonists
Request for Sample to know more @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight
Dystrophic Epidermolysis Bullosa Therapeutics Assessment
The Dystrophic Epidermolysis Bullosa Pipeline report presents a kaleidoscopic view of the DEB emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
By Stage
By Molecule Type
By Route of Administration
By Mechanism of Action
By Targets
Table of Contents
1
Report Introduction
2
Executive Summary
3
Dystrophic Epidermolysis Bullosa Disease Overview
4
DEB Pipeline Therapeutics Comparative Analysis
5
Dystrophic Epidermolysis Bullosa Therapeutic Assessment
6
Dystrophic Epidermolysis Bullosa – DelveInsight’s Analytical Perspective
7
In-depth Commercial Dystrophic Epidermolysis Bullosa Assessment
8
Dystrophic Epidermolysis Bullosa Collaboration Deals
9
Late Stage Dystrophic Epidermolysis Bullosa Products (Phase III)
10
Mid-Stage Dystrophic Epidermolysis Bullosa Products (Phase II)
11
Early Stage Dystrophic Epidermolysis Bullosa Products (Phase I)
12
Pre-clinical and Discovery Stage DEB Products
13
Inactive Dystrophic Epidermolysis Bullosa Pipeline Products
14
Key Dystrophic Epidermolysis Bullosa Products
15
Unmet Needs
16
DEB Market Drivers and Barriers
17
Future Perspectives and Conclusion
18
Analyst Views
19
Key Dystrophic Epidermolysis Bullosa Companies
20
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight